Yes. A transgender man can have a period, because menstruation depends on having a uterus and ovaries, not on gender identity. Many trans men and nonbinary people who retain those organs continue to menstruate, especially before testosterone suppresses ovulation. Testosterone usually reduces or stops bleeding over months, but it is not a reliable contraceptive and breakthrough bleeding can occur.
The hormonal mechanism behind menstrual bleeding
Menstruation is an inflammatory shedding event driven by falling levels of two hormones: estrogen and progesterone. In a typical cycle, the ovaries release an egg around mid-cycle, then produce progesterone for roughly 14 days to prepare the uterine lining, the endometrium. If no pregnancy occurs, the corpus luteum (the remnant follicle) regresses, progesterone collapses, and the lining detaches. That detachment is the period.
Testosterone interrupts this cascade at the top. It acts on the brain's gonadotropin-releasing hormone (GnRH) pulse generator and suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Lower LH and FSH mean less ovarian follicle recruitment, less estrogen, and often no ovulation. No ovulation means no progesterone rise and no true secretory lining to shed.
A parallel mechanism matters for bleeding: testosterone supports endometrial atrophy. A thin, understimulated lining is less likely to bleed, and when it does, the volume is usually lighter and shorter. The endometrium is not inert tissue; it responds to androgen signaling and to the altered hormonal milieu, which is why some patients on stable testosterone develop a persistently thin lining on imaging.
The key caveat: suppression is dose- and time-dependent and individually variable. Ovarian activity can persist at lower exposure levels, which is why bleeding patterns differ so widely among trans men on the same regimen.
How often testosterone stops periods, and how fast
Testosterone is not an on/off switch for the uterus. Cessation is gradual, and the timeline is wide.
In general clinical experience, a substantial share of trans men on masculinizing doses stop having periods within the first several months. A meaningful minority continue to bleed intermittently for longer, and a smaller group never fully stops. Published cohort data report amenorrhea rates that vary by regimen, route, dose, and follow-up length, which is why no single percentage should be quoted as universal.
The timeline below reflects the typical pattern clinicians describe; it is a general course, not a guarantee for any individual.
| Time on testosterone | Typical bleeding pattern |
|---|---|
| Weeks 0-4 | Cycles may continue unchanged or become irregular |
| Months 1-3 | Bleeding often lighter, shorter, or unpredictable |
| Months 3-6 | Many people reach amenorrhea; others still bleed |
| Months 6-12 | Most, but not all, reach amenorrhea |
| Beyond 12 months | Continued bleeding warrants evaluation |
| Any time | One heavy or prolonged bleed needs prompt review |
A counterintuitive detail: heavier or prolonged bleeding can appear during early androgen therapy even as cycles become irregular. This is one reason new bleeding on testosterone is a clinical question, not just an inconvenience.
Breakthrough bleeding and the diagnostic question
Breakthrough bleeding on testosterone has multiple causes, and distinguishing them changes management. The most common benign explanations include endometrial atrophy with fragile vessels, subtherapeutic dosing, missed doses, and route changes. A missed injection or a gap in gel application can allow ovarian activity to resume and trigger a bleed.
Endometrial atrophy is underappreciated as a bleeding source. A very thin lining can shed irregularly and produce spotting rather than a full flow. This is different from a normal cycle and often responds to adjusting the hormonal regimen under a clinician's direction.
Persistent bleeding is the scenario that needs evaluation. It can reflect incomplete ovarian suppression, a polyp, fibroids, or, rarely, endometrial pathology. The threshold clinicians commonly use is bleeding that persists past about six to twelve months of documented adequate testosterone exposure, or any new heavy bleeding.
The professional caveat doctors emphasize: testosterone is not a contraceptive. Suppression of bleeding does not prove suppression of ovulation, and pregnancies have occurred in trans men on testosterone, including those who believed their periods had stopped.
Red-flag symptoms that need prompt medical review
Bulleted warnings, because these change urgency:
Heavy bleeding that soaks through a pad or tampon in about an hour for several hours. Bleeding that lasts longer than about a week, or returns after months of amenorrhea. Severe pelvic pain, fever, or unusual discharge alongside bleeding. Dizziness, fainting, or signs of significant blood loss. A positive pregnancy test with any bleeding. New bleeding in someone whose regimen has been stable for over a year.
Common misconceptions, corrected
The most common misconception is that testosterone reliably ends menstruation. It usually reduces or stops it, but the effect is neither universal nor immediate, and it is dose- and time-dependent.
A second misconception is that a trans man on testosterone cannot become pregnant. Ovulation can persist or resume, particularly with missed doses or lower exposure, so contraception decisions should be made explicitly with a clinician (see guidance from the American College of Obstetricians and Gynecologists and the World Professional Association for Transgender Health).
A third is that amenorrhea on testosterone means the uterus is "shut down" and needs no monitoring. The endometrium remains a tissue of clinical interest, and persistent bleeding deserves the same workup it would get in any patient.
A fourth is that a period on testosterone signals the hormone is "not working." More often it reflects timing, route, adherence, or individual biology rather than treatment failure.
A fifth misconception: trans men who have had a hysterectomy and oophorectomy cannot have a period. That is correct for true menstrual bleeding, but vaginal bleeding after those surgeries has other causes and should be evaluated, not attributed to a cycle.
Practical steps and decision points
Concrete actions reduce uncertainty:
Track bleeding dates, duration, and volume for at least three months. Confirm dosing adherence and injection timing with the prescribing clinician before assuming treatment failure. Discuss contraception separately from gender-affirming hormone therapy, because the two goals are distinct. Report any bleeding past roughly six to twelve months of stable therapy for evaluation. Ask whether the regimen dose and route are adequate for the individual's goal. Seek urgent care for the red-flag symptoms above.
The threshold reconciliation matters: clinicians use "about six months" for expected amenorrhea and "about twelve months" as the outer window before persistent bleeding clearly warrants workup. Use the longer window as the escalation point and the shorter one as a check-in prompt.
Limits of what the evidence can say
Much of the data on transgender men and menstruation comes from observational cohorts, not randomized trials, so causal claims about exact amenorrhea rates are limited. Individual responses to testosterone vary with dose, route, genetics, body composition, and adherence. This article describes mechanisms and general patterns, not a personal treatment plan. Decisions about hormone dosing, contraception, and bleeding evaluation belong with a qualified clinician who knows the individual's history (see guidance from the World Professional Association for Transgender Health).